These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25101884)

  • 21. [Therapeutic update in cystic fibrosis].
    Durupt S; Nove Josserand R; Durieu I
    Rev Med Interne; 2014 Jun; 35(6):388-92. PubMed ID: 24309546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ivacaftor in a G551D homozygote with cystic fibrosis.
    Harrison MJ; Murphy DM; Plant BJ
    N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763
    [No Abstract]   [Full Text] [Related]  

  • 23. Excitement mounts for first disease-modifying cystic fibrosis drugs.
    Opar A
    Nat Rev Drug Discov; 2011 Jul; 10(7):479-80. PubMed ID: 21720393
    [No Abstract]   [Full Text] [Related]  

  • 24. First cystic fibrosis drug advances towards approval.
    Sheridan C
    Nat Biotechnol; 2011 Jun; 29(6):465-6. PubMed ID: 21654649
    [No Abstract]   [Full Text] [Related]  

  • 25. New and Emerging Treatments for Cystic Fibrosis.
    Barry PJ; Jones AM
    Drugs; 2015 Jul; 75(11):1165-75. PubMed ID: 26091951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cystic fibrosis drug Vertex's latest triumph.
    Ledford H
    Nat Biotechnol; 2012 Mar; 30(3):201-2. PubMed ID: 22398597
    [No Abstract]   [Full Text] [Related]  

  • 27. Structure-based discovery of CFTR potentiators and inhibitors.
    Liu F; Kaplan AL; Levring J; Einsiedel J; Tiedt S; Distler K; Omattage NS; Kondratov IS; Moroz YS; Pietz HL; Irwin JJ; Gmeiner P; Shoichet BK; Chen J
    Cell; 2024 Jul; 187(14):3712-3725.e34. PubMed ID: 38810646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutation-specific therapy in cystic fibrosis: the earlier, the better.
    Tümmler B
    Lancet Respir Med; 2013 Oct; 1(8):591-592. PubMed ID: 24461654
    [No Abstract]   [Full Text] [Related]  

  • 29. Cystic fibrosis in an era of genomically guided therapy.
    Barrett PM; Alagely A; Topol EJ
    Hum Mol Genet; 2012 Oct; 21(R1):R66-71. PubMed ID: 22914736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapy for cystic fibrosis--the end of the beginning?
    Davis PB
    N Engl J Med; 2011 Nov; 365(18):1734-5. PubMed ID: 22047565
    [No Abstract]   [Full Text] [Related]  

  • 31. Ivacaftor for patients with cystic fibrosis.
    Wainwright CE
    Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Personalized medicine. New cystic fibrosis drug offers hope, at a price.
    Kaiser J
    Science; 2012 Feb; 335(6069):645. PubMed ID: 22323790
    [No Abstract]   [Full Text] [Related]  

  • 33. Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels.
    Kopeikin Z; Yuksek Z; Yang HY; Bompadre SG
    J Cyst Fibros; 2014 Sep; 13(5):508-14. PubMed ID: 24796242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current development of CFTR potentiators in the last decade.
    Spanò V; Venturini A; Genovese M; Barreca M; Raimondi MV; Montalbano A; Galietta LJV; Barraja P
    Eur J Med Chem; 2020 Oct; 204():112631. PubMed ID: 32898816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation between Ivacaftor-induced CFTR Activation in Airway Epithelial Cells and Improved Lung Function: A Proof-of-Concept Study.
    Debley JS; Barrow KA; Rich LM; Singh P; McKone EF; Nichols DP
    Ann Am Thorac Soc; 2020 Aug; 17(8):1024-1027. PubMed ID: 32421352
    [No Abstract]   [Full Text] [Related]  

  • 36. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.
    Heltshe SL; Mayer-Hamblett N; Burns JL; Khan U; Baines A; Ramsey BW; Rowe SM;
    Clin Infect Dis; 2015 Mar; 60(5):703-12. PubMed ID: 25425629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic ivacaftor treatment: getting F508del-CFTR into more trouble?
    Mall MA; Sheppard DN
    J Cyst Fibros; 2014 Dec; 13(6):605-7. PubMed ID: 25458465
    [No Abstract]   [Full Text] [Related]  

  • 38. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation.
    Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
    Clin Otolaryngol; 2015 Feb; 40(1):16-21. PubMed ID: 25145599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CFTR mutations and cystic fibrosis.
    Prescrire Int; 2013 Oct; 22(142):232. PubMed ID: 24298580
    [No Abstract]   [Full Text] [Related]  

  • 40. FDA OKs first in vitro route to expanded approval.
    Kingwell K
    Nat Rev Drug Discov; 2017 Sep; 16(9):591-592. PubMed ID: 28860581
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.